Macular Degeneration Treatment Market Size is projected to reach USD 15.16 billion by 2030, growing at a CAGR of 7.06%: Straits Research

Advertisement

The global macular degeneration treatment market size was valued at USD 8,208.70 million in 2021. It is expected to reach USD 15,167.69 million by 2030, growing at a CAGR of 7.06% during the forecast period (2022–2030), The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period.

New York, United States, June 19, 2023 (GLOBE NEWSWIRE) — The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see objects. It manifests when the capillaries close to the fovea enlarge and leak. The fluid buildup interferes with light reflection, which causes progressive vision loss. Nutritional therapy can aid treatment in the early stages of dry macular degeneration. A healthy diet rich in antioxidants is part of the plan to sustain the macula’s cells.


Advertisement

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample 


Rising Impact of Retinal Disorder Drivers on the Global Market

The rising prevalence of retinal diseases has increased the demand for macular degeneration treatment. Eye conditions have emerged as potential threats in many developed and developing countries. Globally, the prevalence of the most severe eye conditions is rising, and vision loss is becoming a serious public health concern. Numerous worldwide retinal diseases that impair vision have been identified by the World Health Organization (WHO). Two of these conditions, refractive errors, and age-related macular disorders, are most prevalent in underdeveloped countries. As a result of the rising prevalence of retinal disorders, it is anticipated that the market for treating macular degeneration will expand significantly over the forecast period.

Rapid Aging Population Creates Tremendous Opportunities

According to the UN’s World Aging Report, 703 million individuals were 65 or older in 2019. By 2050, this number is anticipated to double. The population aged 65 and older increased globally from 6% in 1990 to 9% in 2019. Smart contact lenses and intelligent optometry are two examples of cutting-edge and digital healthcare products that may impact the market under consideration. Future developments in digital technology could affect eye care. Future access to gene chips could lead to more accurate AMD and glaucoma diagnosis and treatment. Due to investments made by businesses and accelerated research, the market is anticipated to grow during the forecast period.


Report Scope

Report Metric Details
Market Size by 2030 USD 15,167.69 million
Market Size in 2021 USD 8,208.70 million
CAGR 7.06% (2022-2030)
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Type, Stage of Disease, Route of Administration, Sales Channels
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Novartis AG, Pfizer Inc., Panoptica, Bausch Health Companies Inc., Regeneron Pharmaceutical Inc., Aerie Pharmaceutical Inc., REGENXBIO Inc., and Bayer AG
Key Market Opportunities Rapid Aging Population
Key Market Drivers Rising Impact of Retinal Disorders
Improving Investments in Research and Development

Buy Now Full Report @ https://straitsresearch.com/buy-now/macular-degeneration-treatment-market


Regional Analysis

North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period. The United States represents a sizable portion of the market under study due to several factors, including the burden of the aging population and the prevalence of age-related macular degeneration. The US is dedicated to improving overall population eye health through several initiatives. Along with recent product launches and established healthcare infrastructure, it is also anticipated that the presence of the major market players will hasten the market’s expansion in the United States. Novel macular degeneration treatments are expected to fuel market growth in the United States.

Europe is expected to grow at a CAGR of 6.70%, generating USD 3,531.14 million during the forecast period. The aging population, the rising prevalence of macular degeneration, and sizable R&D expenditures are additional factors influencing the expansion of the French market under investigation. In France, there are an increasing number of cutting-edge research studies being carried out. The funding provided by the government, both at the national and EU agency levels, is primarily to blame. Medical costs are covered by the government and the individual in France, which has one of the best healthcare systems. Over the anticipated period, it is anticipated that these campaigns will increase public awareness and spur rapid market growth in France.

The presence of significant market players, the rising elderly population in Japan, and the rising awareness of macular degeneration in Asia-Pacific all point to a substantial expansion of the Japanese market for macular degeneration treatments. Japan is one of the Asian countries that is aging quickly. In June 2019, Sumitomo Dainippon Pharma Co. Ltd. modified its contract with Healios K.K. for joint development initiatives and other cooperative activities in Japan. The modifications concerned the activities of development and commercialization. Joint development activities will generate retinal pigment epithelial cells from iPS cells to treat age-related macular degeneration and other eye diseases. Due to the rising AMD prevalence and research and development efforts in the area, the market for macular degeneration treatments in Japan is anticipated to increase.


Key Highlights

  • The global macular degeneration treatment market size was valued at USD 8,208.70 million in 2021. It is expected to reach USD 15,167.69 million by 2030, growing at a CAGR of 7.06% during the forecast period (2022–2030).
  • Based on type, the global macular degeneration treatment market is bifurcated into dry and wet age-related macular degeneration. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period.
  • Based on the stage of disease, the global macular degeneration treatment market is bifurcated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment owns the highest market share and is expected to grow at a CAGR of 7.03% during the forecast period.
  • Based on the route of administration, the global macular degeneration treatment market is bifurcated into the intravenous route and intravitreal route. The intravitreal route segment is the highest contributor to the market and is expected to grow at a CAGR of 7.10% during the forecast period.
  • Based on sales channels, the global macular degeneration treatment market is bifurcated into ambulatory surgical centers and hospitals. The hospital segment owns the highest market share and is expected to grow at a CAGR of 7.04% during the forecast period.
  • North America is the most significant shareholder in the global macular degeneration treatment market and is expected to grow at a CAGR of 7.10% during the forecast period.

Competitors in Macular Degeneration Treatment Market

  • Novartis AG
  • Pfizer Inc.
  • Panoptica
  • Bausch Health Companies Inc.
  • Regeneron Pharmaceutical Inc.
  • Aerie Pharmaceutical Inc.
  • REGENXBIO Inc.
  • Bayer AG


Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/macular-degeneration-treatment-market/request-sample


Segmentation of Macular Degeneration Treatment Market

By Type

  • Dry Age-related Macular Degeneration
  • Wet Age-related Macular Degeneration

By Stage of Disease

  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD

By Route of Administration

  • Intravenous Route
  • Intravitreal Route

By Sales Channels

  • Ambulatory Surgical Centers
  • Hospitals
  • Other Sales Channels

By Regions

  • North America
  • Europe
  • Asia-Pacific
  • The Middle East and Africa
  • South America

TABLE OF CONTENT

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Market Definition
    3. Limitations & Assumptions
    4. Market Scope & Segmentation
    5. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    4. Investment Landscape
    5. New Business Models / Revenue Streams
    6. TAM
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Human Factors
    6. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    3. Sales And Distribution Channel Analysis
    4. Case Study Analysis
    5. Patent Analysis
    6. M & A Agreements & Collabration Analysis
  6. ESG TRENDS
  7. Global Macular Degeneration Treatment Market Size Analysis
    1. Global Macular Degeneration Treatment Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
  8. North America Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
    6. U.S.
    7. Canada
  9. Europe Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
    6. U.K.
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest Of Europe
  10. APAC Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
    6. China
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Taiwan
    12. South East Asia
    13. Rest Of Asia-Pacific
  11. Middle East And Africa Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
    6. UAE
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest Of MEA
  12. LATAM Market Analysis
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Dry Age-Related Macular Degeneration
        1. By Value
      3. Wet Age-Related Macular Degeneration
        1. By Value
    3. By Stage Of Disease
      1. Introduction
        1. Stage Of Disease By Value
      2. Early-Stage AMD
        1. By Value
      3. Intermediate AMD
        1. By Value
      4. Late-Stage AMD
        1. By Value
    4. By Route Of Administration
      1. Introduction
        1. Route Of Administration By Value
      2. Intravenous Route
        1. By Value
      3. Intravitreal Route
        1. By Value
    5. By Sales Channels
      1. Introduction
        1. Sales Channels By Value
      2. Ambulatory Surgical Centers
        1. By Value
      3. Hospitals
        1. By Value
      4. Other Sales Channels
        1. By Value
    6. Brazil
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest Of LATAM
  13. Competitive Assessment
    1. Adoption Matrix
    2. Macular Degeneration Treatment Market Share By Manufacturers
    3. Macular Degeneration Treatment Market Ranking By Revenue For Manufacturers
    4. Average Price By Manufacturers
    5. Vendor Footprint Analysis
  14. Market Players Assessment
    1. Novartis AG
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. Gross Margin
      6. Swot Analysis
      7. Recent Developmments
    2. Pfizer Inc.
    3. Panoptica
    4. Bausch Health Companies Inc.
    5. Regeneron Pharmaceutical Inc.
    6. Aerie Pharmaceutical Inc.
    7. REGENXBIO Inc.
    8. Bayer AG.
  15. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data From Secondary Sources
      2. Primary Data
        1. Key Data From Primary Sources
        2. Breakdown Of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  16. APPENDIX
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  17. DISCLAIMER


Table of Content and Figure @ https://straitsresearch.com/report/macular-degeneration-treatment-market/toc


Recent Development

  • In August 2022, Novartis intends to completely spin off the Sandoz division to establish a standalone business.
  • In September 2022, Bayer will present new cardiorenal results for Kerendia in individuals with early-stage chronic kidney disease and type 2 diabetes (finerenone).


News Media

Global Macular Degeneration Treatment Market Ascends at a Noteworthy CAGR of 7.06%

Global Lacrimal Devices Market to Grow at a CAGR of 3.5%

Posterior Segment Eye Disorders Market Share Extends at a Healthy CAGR of 4.83% by 2031


Have a Look at the Related Research Report

Eye Health Supplements Market: Information by Supplement Category (Antioxidants), Therapeutic Domain (Age-Related Macular Degeneration), Product Type, and Region — Forecast till 2029

Dry Eye Syndrome Treatment Market: Information by Product (Cyclosporine, Artificial Tears), Dosage Form (Liquid Drops, Gel), Disease Type (Evaporative, Aqueous Deficient), and Regions-Forecast Till 2031

Posterior Segment Eye Disorders Market: Information by Product (Drugs and Devices), Application (Macular Degeneration, Glaucoma, and Diabetic Retinopathy), and Regions—Forecast Till 2031

Eye Tracking Market: Information by Type (Optical, Eye Attached Tracking), Application (Healthcare, Consumer Electronics), Component (Hardware, Software), and Region — Forecast till 2030

Lacrimal Devices Market: Information by Product (Intubation Sets, Stents And Tubes, Dilators), Applications (Glaucoma, Dry Eye, Lacrimal Gland Inflammation), and Regions—Forecast Till 2031


About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.


For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: [email protected]

Follow Us: LinkedIn | Facebook | Instagram | Twitter

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.